Could a diabetes pill save lives in septic shock?

NCT ID NCT07488689

First seen Apr 18, 2026 · Last updated Jun 16, 2026 · Updated 8 times

Summary

This study tests whether dapagliflozin, a drug used for diabetes, can help people with septic shock—a severe infection that causes organ failure. The drug aims to protect blood vessels and reduce inflammation. About 568 ICU patients will receive either dapagliflozin or a placebo, and researchers will track survival and recovery over 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hôpital Civil, Service de médecine intensive et réanimation, Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.